PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NCT03701022 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
61
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University